Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer: a Multicenter, Single-arm, Prospective Phase II Trial

NCT05606263 is registered in ClinicalTrials.gov with Xi'an Jiaotong University as lead sponsor.

NCT NCT05606263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05606263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer: a Multicenter, Single-arm, Prospective Phase II Trial
Lead sponsor
Xi'an Jiaotong University
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2022
Completion date
November 30, 2025
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer